Printer Friendly

Terumo Introduces New Proprietary Oxygenator to Market.

Tokyo, Japan, Sept 13, 2005 - (JCNN) - Terumo announced on September 12 that it has begun marketing the CAPIOX RX15, a new model in its proprietary oxygenator series, to medical institutions across Japan. The new product features a smaller priming volume (135ml) while improving its gas exchange performance.

Offered at an NHI reimbursement price of 208,000 yen ($1,890), the new oxygenerator is suitable for use for a wide range of patients from infants to adults.

Japan has about 40,000 cardiac surgeries a year. Terumo is aiming for sales of 400 million yen ($3.6 mil) in fiscal 2005. The company also plans to market the CAPIOX RX15 overseas, first in Asia and then in Europe and the US.

Source: JCN http://www.japancorp.net

Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2005 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Sep 13, 2005
Words:136
Previous Article:Takeda Pharmaceutical's ACTOS Oral Antidiabetic Agent Proves in the PROactive Study to Reduce Risk of Heart Attack and Stroke in Type 2 Diabetics.
Next Article:CTC to Market Symyx Technologies' e-Lab Notebook Solution for Chemists.


Related Articles
Eiken Chemical Transfers Manufacturing and Marketing Rights of Two Contrast Agents to Guerbet Japan.
Terumo Acquires Exclusive Sales Rights for Three Contrast Agents from Guerbet AG.
Terumo Completes Twentieth Case of DuraHeart Artificial Heart Implantation.
Terumo Introduces New Central Venous Catheter.
Hisamitsu Pharmaceutical to Transfer Three Clinical Nutrient Products to Terumo.
Terumo Begins Shipping New Nutritional Food Supplement for Elderly.
Terumo to Make Full Entry into Market for Catheter-based Treatment for Cerebral Vascular Disease.
Terumo to Set up Medical Equipment Production Base in Vietnam.
Yakult Honsha, Terumo to Co-develop Liposomal Formulation of Irinotecan.
Terumo, Tanabe Seiyaku Jointly Launch Amigrand IV Infusion.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters